Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) and increased the price target to $459.00 from $450.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Terence Flynn’s rating is based on a combination of factors related to Vertex Pharmaceuticals’ recent financial performance and future guidance. The company’s fourth-quarter revenue exceeded expectations, demonstrating strong sales within its cystic fibrosis franchise, though these results were partly due to temporary factors such as price increases and settlements. Despite the revenue beat, the earnings per share were in line with projections, indicating stable profitability.
Looking forward, Vertex’s 2025 revenue guidance suggests a conservative outlook, with projected figures slightly above the previous year’s actual results. The company is also expected to face challenges from generic competition in international markets, particularly impacting the first quarter of 2025. As a result, Flynn maintains a Hold rating, reflecting a cautious stance given the mixed outlook and potential risks related to future revenue streams.
In another report released today, Barclays also maintained a Hold rating on the stock with a $467.00 price target.